Literature DB >> 2680275

Quality assurance and monitoring in the Hypertension Prevention Trial. Hypertension Prevention Trial Research Group.

G J Prud'homme1, P L Canner, J A Cutler.   

Abstract

The Hypertension Prevention Trial (HPT), was a randomized, controlled, multicenter (four clinics, four resource centers) trial designed to test the feasibility of achieving and sustaining dietary changes in the intake of calories, sodium, and potassium and to assess the effect of those changes on blood pressure in a normotensive population. The trial involved 841 men and women (plus a test cohort of 78) who, at the first baseline (BL) examination were in the age range of 25-49 years and had diastolic blood pressure (DBP) greater than or equal to 76 but less than 100 mm Hg (average of two readings), and at the examination prior to randomization (BL 2) had DBP greater than or equal to 78 but less than 90 mm Hg (also averaged). Participants were randomly assigned to a control treatment group (no dietary counseling) or to one of four dietary treatment groups involving counseling designed to reduce calorie intake, reduce sodium intake, reduce sodium and calorie intake, and reduce sodium and increase potassium intake. This chapter describes HPT procedures for training and certifying clinic staff, for data entry checks and data audits of its distributed data entry system, and for inspecting clinical equipment. Replicate analyses were performed regularly by the two arms of the Data Coordinating Center. The Food Coding Center and the Central Laboratory were evaluated by both internal and external monitoring techniques. The performance monitoring report, prepared semiannually for the governing committees of the HPT, reported on the effectiveness of quality assurance procedures and served to alert staff to developing problems.

Entities:  

Mesh:

Year:  1989        PMID: 2680275     DOI: 10.1016/0197-2456(89)90044-5

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  8 in total

Review 1.  Defining and improving data quality in medical registries: a literature review, case study, and generic framework.

Authors:  Danielle G T Arts; Nicolette F De Keizer; Gert-Jan Scheffer
Journal:  J Am Med Inform Assoc       Date:  2002 Nov-Dec       Impact factor: 4.497

2.  Interviewer variability - quality aspects in a case-control study.

Authors:  Kerstin J Blomgren; Anders Sundström; Gunnar Steineck; Bengt-Erik Wiholm
Journal:  Eur J Epidemiol       Date:  2006       Impact factor: 8.082

Review 3.  Reduced dietary salt for the prevention of cardiovascular disease.

Authors:  Rod S Taylor; Kate E Ashton; Tiffany Moxham; Lee Hooper; Shah Ebrahim
Journal:  Cochrane Database Syst Rev       Date:  2011-07-06

4.  Monitoring clinical research: an obligation unfulfilled.

Authors:  C Weijer; S Shapiro; A Fuks; K C Glass; M Skrutkowska
Journal:  CMAJ       Date:  1995-06-15       Impact factor: 8.262

Review 5.  Reduced dietary salt for the prevention of cardiovascular disease.

Authors:  Alma J Adler; Fiona Taylor; Nicole Martin; Sheldon Gottlieb; Rod S Taylor; Shah Ebrahim
Journal:  Cochrane Database Syst Rev       Date:  2014-12-18

6.  Quality assurance of data collection in the multi-site community randomized trial and prevalence survey of the children's healthy living program.

Authors:  Ashley Yamanaka; Marie Kainoa Fialkowski; Lynne Wilkens; Fenfang Li; Reynolette Ettienne; Travis Fleming; Julianne Power; Jonathan Deenik; Patricia Coleman; Rachael Leon Guerrero; Rachel Novotny
Journal:  BMC Res Notes       Date:  2016-09-02

7.  Quantifying data quality for clinical trials using electronic data capture.

Authors:  Meredith L Nahm; Carl F Pieper; Maureen M Cunningham
Journal:  PLoS One       Date:  2008-08-25       Impact factor: 3.240

8.  Quality Control Measures over 30 Years in a Multicenter Clinical Study: Results from the Diabetes Control and Complications Trial / Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study.

Authors:  Gayle M Lorenzi; Barbara H Braffett; Valerie L Arends; Ronald P Danis; Lisa Diminick; Kandace A Klumpp; Anthony D Morrison; Elsayed Z Soliman; Michael W Steffes; Patricia A Cleary
Journal:  PLoS One       Date:  2015-11-03       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.